VOR Historical PE Ratio Notes

— Vor Biopharma (ticker: VOR) is a clinical-stage biotechnology company focused on developing novel therapies for cancer, specifically by engineering hematopoietic stem cells to be resistant to certain targeted therapies, allowing for more effective treatment of blood cancers like acute myeloid leukemia (AML). The company’s platform aims to fundamentally improve patient outcomes by enabling the use of powerful immunotherapies that would otherwise harm healthy cells. As you review historical price, earnings, and PE ratio data for VOR, it’s crucial to understand that, like many early-stage biotechs, Vor Biopharma has not yet achieved consistent or positive earnings, often resulting in negative or undefined PE ratios during most periods. This is typical for companies in the pre-commercial or research & development phase, where valuation is largely driven by future potential rather than current profits. Thus, historical PE ratios may not provide traditional insight since they reflect ongoing investment in research rather than established revenue streams. Instead, market valuation tends to hinge on clinical milestones, the perceived value of the pipeline, & broader sector sentiment, leading to high volatility or a lack of consistent PE ratio comparability over time.

On this page we presented the Vor Biopharma Historical PE Ratio information for Vor Biopharma' stock. The average VOR historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average VOR historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this VOR historical PE result, against the recent PE: when this page was posted on 5/15/2026, the most recent closing price for VOR had been 14.63, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on VOR or any other given stock, valuation analysis for VOR can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Vor Biopharma PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for VOR. Thanks for visiting, and the next time you need to research VOR Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.